Overview

DOACs in Transition: Examining the Challenges and Complexity of Transitions in Care

The Expert Circle

Click the"View Activity" button to view this activity.

View Activity

CME/CE is no longer available for this activity

Format

Clinical Commentary

Time to Complete

1.00 hr(s).

Release Date

July 09, 2021

Expires On

July 09, 2022

Why should hospitalists, cardiologists, and other clinicians care about optimal post-discharge prophylaxis in patients with acute medical illness? What strategies are available to better ensure optimal post-discharge prophylaxis in this patient population? This clinical commentary features leading thrombosis expert, Dr. Alex Spyropoulos, and a multidisciplinary panel, covering these important questions and how clinicians can ensure that they optimally incorporate these recommendations into their health system.

This activity is intended for clinical cardiologists, vascular surgeons, interventional cardiologists, hospitalists and primary care physicians.

The purpose of this activity is to provide learners with an engaging, practical presentation to help them optimize post-discharge prophylaxis in their acutely ill medical patients. Faculty highlight the latest strategies (e.g. tools, EHR systems) to facilitate optimal post-discharge prophylaxis in this patient population. Learners post-activity will be better able to discuss limitations of various VTE prophylaxis guideline recommendations for these patients in the context of recent evidence as well as interpret the latest data on DOACs as to develop VTE prophylaxis plans for these patients.

Upon completion of this activity, participants will be able to:
• Optimize anticoagulant therapy for patients with acute medical illness post-discharge
• Discuss limitations of various VTE prophylaxis guideline recommendations for patients with acute medical illness in the context of recent evidence
• Interpret the latest data on DOACs to develop strategies optimizing post-discharge VTE prophylaxis in patients with acute medical illness
• Identify patients that would benefit from DOAC therapy post-discharge

This activity is supported by an educational grant from Janssen Scientific Affairs, LLC.

This activity was part of a serial learning curriculum. This functionality is no longer available due to activity expiration.

Chair
Alex Spyropoulos, MD, FACP, FCCP, FRCPC
Professor of Medicine - Zucker School of Medicine at Hofstra/Northwell
Professor - Feinstein Institutes for Medical Research
System Director - Anticoagulation and Clinical Thrombosis Northwell Health
Hempstead, NY

Faculty

Mark Goldin, MD

Associate Professor of Medicine - Zucker School of Medicine at Hofstra/Northwell

Hempstead, NY

Gregory Piazza, MD, MS

Director, Vascular Medicine Section, Division of Cardiovascular Medicine - Brigham and Women's Hospital

Boston, MA

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:

Mark Goldin, MD

Grant/Research Support: Janssen

Gregory Piazza, MD, MS

Grant/Research Support: Amgen, Bayer, BMS/Pfizer Alliance, Boston Scientific Corporation, Janssen, Portola

Alex Spyropoulos, MD, FACP, FCCP, FRCPC

Consultant: Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen, Portola, Sanofi

Grant/Research Support: Boehringer Ingelheim, Janssen

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Rivaroxaban for patients with PAD post-revascularization

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 60% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Laurie Novoryta
lnovoryta@achlcme.org

Overview

DOACs in Transition: Examining the Challenges and Complexity of Transitions in Care

Program Description

Intended Audience

Activity Purpose

Learning Objectives

Provider Information

Supporter Information

Serial Learning

Faculty

Faculty Disclosure

Staff Disclosure

Disclaimer

Method of Participation

Accreditation and Credit Designation

Program Manager

Related Activities